TRIAL INFORMATION
Sponsor:NovaCell Therapeutics
Therapeutic Area:Oncology
Phase:PHASE III
Indication:Non-Small Cell Lung Cancer (Stage IIIB/IV)
Target Enrollment:45 patients
Est. Duration:30 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
TOTAL POOL
2,500
AVAILABLE
2,080
420 allocated
REQUIRED
45
ADEQUACY RATIO
46.2x
Pool Utilization
Current Allocation16.8%
If This Trial Accepted18.6%
Pool is Sufficient
Available pool is 46.2x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100